NCT06203600 2026-03-17
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
National Cancer Institute (NCI)
Phase 2/3 Recruiting
National Cancer Institute (NCI)
ALX Oncology Inc.
Compass Therapeutics
Seagen Inc.
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
1Globe Biomedical Co., Ltd.
RemeGen Co., Ltd.
Shanghai JMT-Bio Inc.
Shanghai Zhongshan Hospital
Peking University
Qilu Pharmaceutical Co., Ltd.
ChineseAMS
Velindre NHS Trust
Peking University